First drug candidate (PNA-1) in human phase 2a (pilot);
Second drug candidate (PNA-6) in R&D and FDA approval process.
The workload for physicians, hospitals, home health care workers and other medical professionals will be decreased. Patients will remember to pick-up and take their medications (medication compliance is a HUGE problem with aging patients and "forgetting to take my meds" is the most often explanation. Improved memory and cognition will also allow patients to better assess and describe their health symptoms to medical professionals and care for minor health problems at home. All these benefits combined will decrased the workload and cost associated with seniors health care.
Most hospital re-admissions following cardiac by-pass surgery is complications from the failure of the patient to remember to take his/her medicatons. This is also true for other medical conditions such as orthopedic surgeries. Given that the healthcare system will soon change from reimbursement by procedure to reimbursement by outcome, re-admissions will have significant financial impacts on hospitals. Also, while in a hospital, greater number and type of medical staff are required to provide and supervise the care of a patient with cognitive deficits and memory loss. Patients are much easier to manage if they don't have these co-existing conditions. Such results in a definite financial impact on the hospital.
The model for taking a new medical innovation to market has changed over the past 10 years. No longr do mid- to large-pharma size pharma partners conduct their own research or maintain their own lab facilities. It's simply too expensive. Rather, they allow for tested technologies to rise to the top during the phase 2 druge R&D and clinical phase of drug development.Likewise, companies who are good at innovaton -- working in laboratories, collaborating with colleagues and writing grants for exttrmurial fundin are best done universities. The skills and tools it takes to take a drug market are very different than those reuquired to develop the drug. The relationship between the pharma companies and the R&D.early-stage technology developers synergistic and complimentary and all interactions between the two should be done in those ways.
No updates found .